Abstract: The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, ?-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and ?2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipep

Abstract: A process for the manufacture of isoquinoline and 1,7-naphthyridine derivatives of formula wherein R1, R2, R3, R4 and X have the meanings as indicated in the specification. The process utilizes readily available starting materials of the formulae or compounds prepared from such starting materials wherein R1, R2, R3 and X have meanings as defined for formula (I); and R and R5 are independently C1-C7-alkyl.